Amifampridine ( DrugBank: Amifampridine )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
3	脊髄性筋萎縮症	4
11	重症筋無力症	4
12	先天性筋無力症候群	1

3. 脊髄性筋萎縮症

臨床試験数 : 237 / 薬物数 : 123 - (DrugBank : 29) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 75

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03819660 (ClinicalTrials.gov)	March 7, 2019	23/1/2019	Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3	Long Term Safety Study of AmifampridinePhosphate in Ambulatory Patients With Spinal Muscular Atrophy ...	Muscle Atrophy	Drug: Amifampridine Phosphate 10 MG Oral Tablet	Catalyst Pharmaceuticals, Inc.	NULL	Enrolling by invitation	6 Years	50 Years	All	12	Phase 2	Italy
2	NCT03781479 (ClinicalTrials.gov)	January 21, 2019	18/12/2018	Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients	A Randomized, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of Amifampridi ...	Muscular Atrophy, Spinal	Drug: Amifampridine Phosphate;Drug: Placebo Oral Tablet	Catalyst Pharmaceuticals, Inc.	NULL	Completed	6 Years	50 Years	All	13	Phase 2	Italy
3	EUCTR2018-000160-28-IT (EUCTR)	06/11/2018	24/05/2021	Clinical study evaluating the long term safety of amifampridinephosphate in ambulatory patients with ...	Long term safety study of amifampridinephosphate in ambulatory patients with Spinal Muscular Atrophy ...	Spinal Muscular Atrophy (SMA) Type 3 MedDRA version: 20.1;Level: PT;Classification code 10041582;Ter ...	Trade Name: FIRDAPSE - 10 MG - COMPRESSE - USO ORALE - BLISTER(ALU/PVC/PVDC) 100 X 1 COMPRESSE Produc ...	CATALYST PHARMACEUTICALS INC.	NULL	Not Recruiting			Female: yes Male: yes	12	Phase 2	Italy
4	EUCTR2017-004600-22-IT (EUCTR)	04/04/2018	07/04/2021	Clinical study evaluating the effect of AmifampridinePhosphate in Ambulatory Patients with Spinal Mu ...	A Randomized, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of Amifampridi ...	Spinal Muscular Atrophy (SMA) Type 3 MedDRA version: 20.1;Level: PT;Classification code 10041582;Ter ...	Trade Name: FIRDAPSE - 10 MG - COMPRESSE - USO ORALE - BLISTER(ALU/PVC/PVDC) 100 X 1 COMPRESSE Produc ...	CATALYST PHARMACEUTICALS INC.	NULL	Not Recruiting			Female: yes Male: yes	12	Phase 2	Italy

First Previous1Next Last

11. 重症筋無力症

臨床試験数 : 332 / 薬物数 : 234 - (DrugBank : 81) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 127

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2017-004777-14-IT (EUCTR)	05/06/2018	21/01/2021	Clinical study evaluating the long term safety of amifampridinephosphate in patients with MuSK antib ...	Long term safety study of amifampridinephosphate in patients with MuSK antibody positive and AChR an ...	MuSK antibody and AChR antibody positive myasthenia gravis MedDRA version: 21.1;Level: PT;Classifica ...	Trade Name: FIRDAPSE - 10 MG - COMPRESSE - USO ORALE - BLISTER(ALU/PVC/PVDC) 100 X 1 COMPRESSE Produc ...	CATALYST PHARMACEUTICALS INC.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	70	Phase 3	United States;Canada;Italy
2	NCT03304054 (ClinicalTrials.gov)	March 7, 2018	28/9/2017	Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG	A Randomized, Placebo-control, Parallel Group Study to Evaluate the Effect of AmifampridinePhosphate ...	Myasthenia Gravis, Generalized	Drug: Amifampridine Phosphate;Drug: Placebo Oral Tablet	Catalyst Pharmaceuticals, Inc.	NULL	Completed	18 Years	N/A	All	70	Phase 3	United States
3	EUCTR2017-004018-25-IT (EUCTR)	22/02/2018	19/01/2021	Clinical study evaluating the effect of Amifampridinephosphate in patients with MuSK antibody positi ...	A Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of AmifampridinePhosph ...	MuSK antibody positive myasthenia gravis MedDRA version: 21.1;Level: PT;Classification code 10028417 ...	Trade Name: FIRDAPSE - 10 MG - COMPRESSE - USO ORALE - BLISTER(ALU/PVC/PVDC) 100 X 1 COMPRESSE Produc ...	CATALYST PHARMACEUTICALS INC.	NULL	Not Recruiting			Female: yes Male: yes	70	Phase 3	United States;Canada;Italy
4	EUCTR2015-003127-62-IT (EUCTR)	02/10/2015	17/03/2017	A Randomized, Placebo-Controlled Study to Evaluate the Effect of Amifampridinein Patients with MuSK ...	A Randomized, Placebo-Controlled, Pilot Crossover Study to Evaluate the Effect of AmifampridinePhosp ...	Patients with MuSK Antibody Positive Myasthenia Gravis MedDRA version: 19.1;Level: LLT;Classificatio ...	Trade Name: FIRDAPSE - 10 MG - COMPRESSE - USO ORALE - BLISTER(ALU/PVC/PVDC) 100 X 1 COMPRESSE Produc ...	FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA	NULL	Not Recruiting			Female: yes Male: yes	20	Phase 2	Italy

First Previous1Next Last

12. 先天性筋無力症候群

臨床試験数 : 5 / 薬物数 : 7 - (DrugBank : 3) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 13

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02189720 (ClinicalTrials.gov)	July 2014	5/7/2014	Expanded Access Study Amifampridine Phosphate in Congenital Myasthenic Syndrome (CMS)	An Open-Label, Expanded Access Protocol for AmifampridinePhosphate Treatment in Patients With Congen ...	Congenital Myasthenic Syndrome	Drug: Amifampridine Phosphate	Catalyst Pharmaceuticals, Inc.	NULL	No longer available	2 Years	N/A	All			United States

First Previous1Next Last

先頭へ